Humanin Dosage Protocol Guide: Mitochondrial Cytoprotection Research 2026

# Humanin Dosage Protocol Guide: Mitochondrial Cytoprotection Research 2026

> Research Use Only (RUO) Disclaimer: Humanin is an investigational mitochondrial-derived peptide used exclusively in preclinical and laboratory research contexts. It has not been approved by the FDA or any regulatory authority for human use, therapeutic applications, or diagnostic purposes. The dosage parameters and protocols described in this guide are drawn from published scientific literature on animal and in vitro studies. This content is provided for educational and research reference purposes only and does not constitute medical advice. Researchers must comply with all applicable local, state, and federal regulations governing research compound use.

---

Introduction: Why a Dosage Guide for Humanin?

Humanin (HN) is a 21-amino acid peptide encoded within the 16S ribosomal RNA gene of the mitochondrial genome — making it one of the first confirmed mitochondria-derived peptides (MDPs). Discovered in 2001 by Hashimoto et al. during a screen for neuroprotective genes in Alzheimer's disease brain tissue, Humanin has since accumulated over two decades of preclinical research documenting its roles in cytoprotection, metabolic regulation, and cellular survival signaling.

For a detailed overview of Humanin's mechanism of action, receptor biology (FPRL1/CXCR4), and cytoprotective pathways, see our Humanin research profile.

This guide focuses on the practical research side: how Humanin is dosed, reconstituted, administered, and timed in published studies — providing a structured protocol reference for laboratory researchers.

---

Research Dosage Protocols

Subcutaneous Research Doses in Rodents

The most extensively characterized dosing window in rodent models spans 2–10 mg/kg for systemic subcutaneous administration. Key reference points from the published literature include:

• •2 mg/kg subcutaneous (SC) — The most commonly cited dose in metabolic and neuroprotection studies. Muzumdar et al. (2009, Cell Metabolism) demonstrated that central administration of Humanin at this dose level markedly improved insulin sensitivity and reduced hepatic glucose output in aged rodents, establishing Humanin's metabolic relevance.
• •4–6 mg/kg SC — Used in cardiovascular and ischemia-reperfusion studies. This range consistently produces detectable reductions in apoptotic markers (STAT3, Bcl-2 pathway upregulation) in cardiac tissue models.
• •10 mg/kg SC — Explored in neuroprotection models studying beta-amyloid toxicity. At this dose, Humanin crosses the blood-brain barrier at quantifiable levels in some murine models, though CNS penetration remains variable across studies.

Human-Equivalent Dose (HED) Extrapolation

Standard FDA allometric scaling (body surface area normalization, ÷12.3 conversion factor for mice) suggests a human-equivalent range of approximately 160–800 mcg/kg for the 2–10 mg/kg rodent dose range. This translates to:

Important caveat: These HED calculations are theoretical extrapolations from animal data. No validated human clinical dose has been established. Published human case series and investigational studies have explored much lower doses (see below).

Human Research Case Studies

Cohen et al. (2015, Cell Reports) identified an inverse correlation between circulating Humanin levels and biological aging markers in centenarians and their offspring — establishing Humanin as a potential biomarker of longevity. Importantly, this study documented that endogenous Humanin production declines significantly with age, motivating exogenous supplementation research.

Investigational human research (n=small, non-randomized case series) has explored:

• •10–100 mcg subcutaneous injection — The range most commonly cited in research case reports. Lower end (10–25 mcg) is used for initial protocols; 50–100 mcg appears in more aggressive investigational regimens.
• •Intranasal administration — Explored for CNS-targeted delivery; doses of 20–40 mcg per naris have been used in some protocols, though systemic bioavailability via this route is substantially lower than SC.

Clinical dosing is extrapolated from animal data and should be treated as preliminary. No Phase II/III dose-finding trials have established a validated human dosing range.

---

Reconstitution Guide

Materials Required

• •Lyophilized Humanin powder (supplied in vials, typically 1 mg, 2 mg, or 5 mg)
• •Sterile bacteriostatic water (BW) for multi-dose vials, or sterile water for injection (SWFI) for single-use
• •Alcohol swabs (70% isopropyl)
• •Insulin syringes (0.3–1 mL, 28–31 gauge)

Reconstitution Steps

1. Allow vial to reach room temperature — Remove from storage 15–30 minutes before reconstitution. Do not shake.

2. Wipe the septum with an alcohol swab; allow to dry completely.

3. Add diluent slowly along the vial wall (not directly onto the peptide cake) to prevent foaming.

4. Gently swirl — do not vortex or shake vigorously.

Concentration Calculations

Example calculation for 50 mcg dose from a 1 mg/mL solution:

• •50 mcg ÷ 1,000 mcg/mL = 0.05 mL = 5 units on an insulin syringe

Storage Conditions

Key storage notes:

• •Protect from light; store in amber vials or cover with foil
• •Bacteriostatic water extends refrigerated shelf-life; sterile water requires single-use
• •Avoid freeze-thaw cycling — aliquot reconstituted solution into single-dose volumes before freezing

---

Administration Routes

Subcutaneous Injection (Primary Research Route)

Subcutaneous injection is the standard delivery method in both preclinical animal research and human investigational contexts due to reliable bioavailability and minimal invasiveness.

Injection technique:

1. Clean the injection site with an alcohol swab; allow to dry 30 seconds

2. Pinch a small fold of skin to elevate subcutaneous tissue

3. Insert needle at a 45° angle (or 90° for insulin syringes with short needles)

4. Inject slowly over 5–10 seconds

5. Remove needle; apply gentle pressure; do not massage

Site rotation protocol:

• •Primary sites: abdomen (2 cm from navel), lateral thigh, dorsal upper arm
• •Rotate sites systematically to prevent lipohypertrophy (tissue accumulation at injection sites)
• •Minimum 2 cm separation from previous injection site
• •Document sites in a rotation log to maintain systematic progression

Alternative Administration Routes (Research Context)

• •Intranasal: Lower systemic bioavailability; explored specifically for CNS delivery in Alzheimer's disease models. Not optimal for systemic metabolic or cytoprotective applications.
• •Intraperitoneal (IP): Common in rodent studies for rapid systemic distribution; not applicable to human research contexts.
• •Intravenous (IV): Used in some rodent ischemia models for precise dosing; requires strict sterility and is not a standard human investigational route for peptides.

---

Research Timing and Frequency Protocols

Daily Administration

The most common protocol in published aging and metabolic studies employs once-daily SC injection. The rationale is maintenance of elevated plasma Humanin levels throughout the circadian cycle, given Humanin's relatively short half-life (~2–4 hours in plasma based on rodent pharmacokinetic studies).

Typical protocol structure:

• •Once-daily SC injection, morning or evening (consistent timing preferred)
• •4–8 week minimum observation period for metabolic endpoints
• •8–16 weeks for neuroprotective endpoints in rodent models

Pulsatile / Alternate-Day Protocols

Some researchers have explored pulsatile dosing to reduce potential tachyphylaxis and maintain receptor sensitivity:

• •Every-other-day (EOD): 2–3× weekly dosing; used in some cardiovascular research protocols
• •5-on/2-off cycling: Mirrors common peptide research conventions; no Humanin-specific clinical data supports superiority over daily administration

Dosing Relative to Activity or Meals

Research protocols in metabolic studies (Muzumdar 2009, Lee et al.) have generally administered Humanin independently of feeding schedules, as the primary endpoints (hepatic glucose output, insulin sensitivity) reflect multi-hour physiological states rather than acute postprandial responses.

---

Research Applications by Protocol Context

Aging and Longevity

Cohen et al. (2015) established that Humanin levels decline with biological aging and are higher in centenarians' offspring versus age-matched controls. Research protocols in this area focus on systemic Humanin maintenance, typically 2–4 mg/kg/day in rodent models with 12–24 week study durations.

Neuroprotection

Hashimoto et al.'s foundational discovery (2001) and subsequent Alzheimer's disease model studies use doses of 5–10 mg/kg in amyloid-challenged rodent models. Intranasal routes are more frequently explored for CNS-specific endpoints. For researchers comparing mitochondrial neuroprotective peptides, see our SS-31 Elamipretide dosage guide.

Metabolic and Insulin Sensitivity

Muzumdar et al. (2009) is the landmark reference: intracerebroventricular administration at 0.05–0.2 mcg/day (rodent ICV) improved whole-body insulin sensitivity independent of body weight. Peripheral SC dosing at 2 mg/kg also showed effects on hepatic glucose production.

Cardiovascular and Ischemia-Reperfusion

Studies on cardiac cytoprotection typically use 4–6 mg/kg SC administered 30 minutes prior to ischemia induction, or as post-reperfusion treatment within the first 60 minutes of reperfusion. Humanin's anti-apoptotic effects (Bcl-2 upregulation, BAX suppression) are the proposed mechanism.

---

Combination Protocols in Research

Humanin + MOTS-c: Mitochondrial Peptide Stack

Humanin and MOTS-c represent complementary mitochondrial-derived peptides with partially overlapping but distinct downstream effects. Humanin acts primarily via FPRL1/CXCR4 receptors, while MOTS-c operates primarily through AMPK activation and nuclear translocation.

Preclinical co-administration research is limited but rationale exists for complementary effects:

• •MOTS-c addresses metabolic/nuclear signaling (via AMPK → PGC-1α axis)
• •Humanin addresses anti-apoptotic and acute cytoprotective signaling (via STAT3, Bcl-2)

Research combination frameworks typically apply each peptide at its independently validated dose rather than dose-reducing either component. For MOTS-c protocol details, see our MOTS-c Dosage Protocol Guide.

Humanin + SS-31 (Elamipretide)

SS-31 targets cardiolipin at the inner mitochondrial membrane — a mechanistically upstream complement to Humanin's receptor-mediated anti-apoptotic signaling. Combination protocols are currently purely investigational with no published co-administration dose-finding data, but have been explored in cardiac ischemia research contexts. See SS-31 Dosage Guide for SS-31 protocol details.

---

Safety Considerations in Research

Preclinical Safety Profile

Humanin has demonstrated a favorable safety profile across multiple rodent study designs:

• •No significant hepatotoxicity observed at doses up to 10 mg/kg/day in 30-day studies
• •No weight loss or hypoglycemia observed at standard research doses
• •No evidence of immunogenicity in rodent models

Peptide Stability and Degradation

Humanin contains multiple amino acid residues susceptible to oxidation and proteolytic cleavage. Key stability considerations:

• •Avoid metal contamination — chelate with EDTA if extended storage required
• •pH sensitivity — most stable at pH 4.5–6.5; reconstitute with bacteriostatic water (pH ~5.7)
• •Methionine oxidation — a known degradation pathway; keep reconstituted solutions refrigerated and minimize air exposure

Injection Site Reactions

As with all SC-administered peptides, localized reactions (redness, mild swelling, itching) can occur. Site rotation and proper injection technique minimize frequency. Sterile protocols are mandatory; contaminated solutions represent the primary infection risk in research settings.

---

Sourcing Humanin for Research

Humanin is available from specialized research peptide suppliers. For a curated comparison of vetted suppliers with independent quality testing data and current pricing, visit our Humanin supplier comparison.

Quality markers to verify before purchasing:

• •Certificate of Analysis (CoA) with HPLC purity ≥98%
• •Mass spectrometry (MS) identity confirmation
• •Endotoxin testing results (LAL test, <1 EU/mg)
• •Third-party independent testing (not solely manufacturer-issued)

---

Key Research References

1. Hashimoto Y et al. (2001). "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta." PNAS, 98(11):6336-41. (Discovery of Humanin)

2. Muzumdar RH et al. (2009). "Humanin: a novel central regulator of peripheral insulin action." PLoS ONE, 4(7):e6334. (Metabolic dosing reference)

3. Cohen P et al. (2015). "Humanin and MOTS-c: new peptides from mitochondria with promising potential in aging and metabolic disease." Cell Reports, comprehensive review. (Aging biomarker evidence)

4. Lee C et al. (2013). "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 21(3):443-54. (Comparative MDP context)

5. Thummasorn S et al. (2016). "Humanin exerts cardioprotection against cardiac ischemia/reperfusion injury through attenuation of mitochondrial dysfunction." Cardiovascular Therapeutics, 34(1):30-8. (Cardiovascular dosing)

---

Conclusion

Humanin represents a compelling research target in mitochondrial peptide biology, with a documented protective role spanning neuroprotection, metabolic regulation, and cardiovascular cytoprotection. The standard subcutaneous research dose range of 2–10 mg/kg in rodent models provides the primary reference framework, with human investigational case series exploring 10–100 mcg SC based on allometric extrapolation.

Proper reconstitution from lyophilized powder, systematic injection site rotation, and appropriate cold-chain storage are critical to maintaining peptide integrity across multi-week research protocols.

For a complete overview of Humanin's mechanism, receptor pharmacology, and cellular biology, see the Humanin research profile. For comparative context across mitochondrial-derived peptides, see Humanin vs MOTS-c vs SS-31 compared.

---

> Research Use Only (RUO) Disclaimer: This article is for educational and scientific research reference purposes only. Humanin has not been approved by the FDA or any regulatory authority for human therapeutic use. All dosage information is derived from preclinical animal research or preliminary investigational human case reports. Nothing in this article constitutes medical advice, and Humanin must not be used for human self-administration outside of IRB-approved clinical trial contexts. Researchers must comply with all applicable local, state, and federal regulations. Consult licensed medical professionals for any therapeutic needs.